BCRP expressing cell lines

Introduction The breast cancer resistance protein (BCRP) is an ATP-binding cassette efflux transporter originally identified by its ability to confer multidrug resistance in cancer cells. BCRP mediates the efflux transport of a broad spectrum of substrates, including many drugs routinely administered to pregnant women to treat various diseases. Given its tissue localization pattern, BCRP is expected to play an important role in absorption, distribution, and elimination of drugs. Indeed, the importance of BCRP in drug disposition has been demonstrated in numerous studies Technology description Researchers at the University of Washington have developed MDCK and LLC-PK1 based cell lines expressing BCRP. The MDCK/BCRP cell line expresses a high level of BCRP and has been used to screen BCRP substrate drugs. The LLC-PK1/BCRP cell does not have Pglycoprotein
(a similar drug transporter) background activity, and is suitable for screening drugs that BCRP inhibits. Business Opportunity This technology provides a novel tool to study BCRP-mediated drug resistance as well as pharmacokinetic drug-drug interactions. The role transporters play in drug-drug interactions is critical because of the profound effect they have on the absorption of drugs and their distribution within the body. In humans, high BCRP gene expression may be linked to chemotherapeutic drug resistance in cancer. Related Publication(s)
Zhou L et al, The Breast Cancer Resistance Protein (Bcrp1/Abcg2) Limits Fetal Distribution of Glyburide in the Pregnant Mouse: An Obstetric-Fetal Pharmacology Research Unit Network and University of Washington Specialized Center of Research Study, Mol Pharmacol 73:949–959, 2008 For more information on this technology contact:
Bolong Cao, Ph.D. Licensing Officer, Invention Licensing bolongc@u.washington.edu 206-685-9348

Type of Offer: Licensing



Next Patent »
« More Biotech Patents
« More Life Sciences Patents

Share on      


CrowdSell Your Patent